Orient Bio Inc

Orient Bio Inc has a liquidity position characterized by a current ratio of 11.26, indicating strong short-term liquidity. The company's price-to-book ratio is 0.77, suggesting that the market value is trading below the book value. The company's free cash flow is negative at -16,028,876,800 KRW, which is a concern for its ability to fund operations and growth without external financing. In terms of profitability, Orient Bio Inc is currently unprofitable, with a net income of -13,194,865,820 KRW and an operating income of -3,076,404,780 KRW. The return on equity is -0.1837, and the return on assets is -0.1556, both indicating poor returns for shareholders and asset utilization. The company's gross profit margin is 24.48%, which is a key metric for the biotechnology and medical research industry. Orient Bio Inc's revenue is derived from various segments, including the production and supply of laboratory animals, CRO services, and the provision of medical and library equipment. The company's geographic exposure is primarily within Korea, and there is no significant revenue concentration in any single segment or region. The company's growth trajectory is uncertain, as it is currently unprofitable and has a negative free cash flow. The outlook for the current fiscal year does not indicate significant revenue growth, and the company may need to secure additional financing to support its operations and expansion plans. The risk assessment for Orient Bio Inc indicates low liquidity and dilution risks. However, the company's negative net income and operating income suggest financial instability. There are no immediate filing-based liquidity or dilution flags, but the company's financial performance may require close monitoring for potential risks. Recent events and filings for Orient Bio Inc do not indicate any significant changes in the company's financial or operational status. The company continues to operate in the biotechnology and medical research industry, providing laboratory animals and CRO services. There are no notable recent events that have impacted the company's financial performance or strategic direction.